Creatine Kinase Reagent Market Size, Share, and COVID-19 Impact Analysis, By Product (Instruments and Reagents & Kits), By Sample Type (Blood, Urine, and Others), By End Users (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Regional Forecast, 2024-2032

The enzyme creatine kinase (CK) is found in the heart and skeletal muscle, with trace levels in the brain. Creatine kinase is released into circulation when the cells of skeletal muscles, cardiac muscles, or the brain get damaged. High CK levels have been associated with myocardial infarction, severe encephalopathy, and other muscle diseases.

The increase in the number of patients with CNS disorders, cardiovascular diseases (CVDs), and muscular diseases is the major factor leading to the growth of the creatine kinase reagent market.

• For instance, according to data published by WHO in July 2022, approximately 1.71 billion people live with musculoskeletal conditions globally.


• Moreover, 17.9 million people associated with CVDs died in 2019 across the world, representing 32% of all global deaths.

Impact of COVID-19 on the Creatine Kinase Reagent Market

The market for creatine kinase reagents was positively impacted by the pandemic of COVID 19 in 2020.

For instance, according to the data provided by NLM in May 2021, an increase in creatine kinase levels was reported in 9%- 33 % of the patients infected with COVID-19. The myopathies and skeletal muscle injury in COVID-19 patients were associated with increased C-reactive proteins, neutrophils, and lymphopenia.

Key Insights

The following key insights will be covered in the report:

• Prevalence of Key Cardiovascular Diseases - By Key Countries/Regions, 2022.


• New Product Launches, Key Players, 2022.


• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.).


• Impact of COVID-19 on the Global Creatine Kinase Reagent Market.

Analysis by Product

Based on product, the market is segmented into instruments and reagents & kits. The reagents & kits segment captured the dominant share in 2022 owing to factors such as an increasing patient pool undergoing Creatine Kinase testing for various conditions. The increasing number of players offering CK test kits, new product approvals, and the introduction of innovative products have also supported segment growth.

• For instance, in February 2023, Singclean introduced a new Creatine Kinase Isoenzyme MB (CK-MB) test kit to expand its product line. This test kit is based on the Fluorescence Immunochromatography method.

Regional Analysis 

On the basis of region, North America captured the largest share in the year 2022. During the forecast period, the region is anticipated to dominate the market. This can be associated to the high prevalence of chronic diseases in the U.S., the high focus on clinical research, and the availability of innovative products in the region.

• According to WHO, cardiovascular diseases are the leading cause of death worldwide. Around 17.9 million people died due to cardiac diseases each year. According to the data published in CDC's 2022 report, cardiac diseases are the leading cause of death in the U.S. Around 805,000 people in the U.S. are suffering from heart attacks yearly.

• In addition, the Heart and Stroke Foundation of Canada, published data in February 2022, around 750,000 people were living with heart failure in Canada. 

The above statistics support the high demand for creatine kinase reagents in the region.

The decrease in levels of creatine kinase in the body leads to congestive heart failure. The more number of heart attacks creates the opportunity for the high utility of creatine kinase reagents to detect and manage complications related to the heart, which accelerates the market growth.

Key Players Covered

The profiles of key players will be included in the report, such as BBI Solutions, Thermo Fisher Scientific Inc., Abbott, Danaher, Boditech Med Inc., Randox Laboratories Ltd., DiaSys Diagnostic Systems GmbH, Novus Biologicals, PerkinElmer Inc., and others.

Segmentation

Key Industry Developments

• February 2023: the three new in vitro diagnostic reagents, were launched by Hangzhou Singclean Medical Products Co., Ltd including a test kit such as Creatine Kinase Isoenzyme MB (CK-MB).


• June 2022: PHC Europe introduced an instrument named PATHFAST at Analytica fair and conference. This instrument is used to detect cardiac parameters and other emergency parameters such as CK-MB mass (creatine kinase-isoenzyme MB), and others.


• July 2021: Beckman Coulter, Inc. entered into definitive agreements with Quidel Corporation. This agreement was signed to get all rights related to the manufacture, sale, and distribution of a BNP assay for Beckman Coulter analyzers.